NCT05510401 (SECURIDRAP) is a NA clinical trial of SECURIDRAP® SELFIA® in Disorientation, sponsored by Groupe Mulliez-Flory.

Who is sponsoring NCT05510401?

NCT05510401 is sponsored by Groupe Mulliez-Flory.

What drugs are being tested in NCT05510401?

Interventions in NCT05510401: SECURIDRAP® SELFIA®.

What condition does NCT05510401 study?

NCT05510401 studies Disorientation, Cognitive Impairment, Behavior Disorders.

Is NCT05510401 still recruiting?

NCT05510401 is currently recruiting now. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT05510401: SECURIDRAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safe Use of SECURIDRAP® SELFIA®

Recruiting now NA Last updated 20 November 2024

What this trial tests

NA trial testing SECURIDRAP® SELFIA® in Disorientation in 108 participants. Currently enrolling.

Timeline

18 May 2022

Primary endpoint
30 March 2025

30 July 2025

Quick facts

Lead sponsor	Groupe Mulliez-Flory
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	108
Start date	18 May 2022
Primary completion	30 March 2025
Estimated completion	30 July 2025
Sites	10 locations across France

Drugs / interventions tested

SECURIDRAP® SELFIA®

Conditions studied

Disorientation — all drugs for Disorientation →
Cognitive Impairment — all drugs for Cognitive Impairment →
Behavior Disorders — all drugs for Behavior Disorders →

Sponsor

Groupe Mulliez-Flory

Who can join

18 and older, any sex, with Disorientation or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interventional, multicenter, prospective and non-comparative clinical investigation carried out in 9 French establishments in order to assess the safety of the SÉCURIDRAP® SELFIA® bedding by mesasuring all the adverse events likend to its use. Following the withdrawal from the market of the first version of the SECURIDRAP® SELFIA®, this clinical investigation is being carried out at the request and on the recommandation of the ASNM in order to assess the safety of the second version of the SECURIDRAP® SELFIA® coating.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05510401 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe Mulliez-Flory
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05510401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing